Antenatal insulin-like growth factor-I and perinatal growth, survival and function of the growth restricted fetus.

产前胰岛素样生长因子-I 与生长受限胎儿的围产期生长、存活和功能。

• 批准号: nhmrc : 104897
• 负责人: Prof Julie Owens
• 金额: $ 10.03万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2000
• 资助国家: 澳大利亚
• 起止时间: 2000-01-01 至 2001-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/antenatal-insulin-like-restricted-fetus/100778
• 关键词: Antenatal; insulin; like; growth; factor

Poor growth before birth or intrauterine growth restriction (IUGR), as indicated by being light, short or thin for stage of pregnancy, greatly increases the risk of illness and death before and after birth and in infancy. IUGR has increased risks of asphyxia, poor glucose control, hypothermia, respiratory difficulties, neurological problems and poor immune function, many of which persist. IUGR is one of the most common clinical problems in obstetrics and neonatology, with ~6% of infants born IUGR in Australia in non-Aboriginal communities and between 7 to 17% in Aboriginal communities. Despite these adverse consequences for health of the individual throughout life, we do not currently have any effective therapies to treat IUGR. Small infants are mostly a result of an inadequate supply of oxygen and nutrients before birth, due to an impaired capacity of the mother to acquire these for the placenta to deliver them to the growing fetus or due to poor functioning of the placenta itself. This intrauterine malnutrition not only slows growth, but impairs the development of a range of body functions leading to the increased risk of illness and death in IUGR. Therapies to be used before birth to treat IUGR need to either restore supply of oxygen and nutrients or to promote growth and functional development. We have discovered that administration of a major growth promoting hormone, insulin-like growth factor-I (IGF-I), to the IUGR fetus, which has low levels of IGF-I, increases its growth. This project will therefore determine if directly giving this hormone in the IUGR fetus will restore development as well as growth before birth, improving function and hence survival and health after birth. If successful, the first effective approach to the antenatal treatment of IUGR will have been identified and would provide the essential knowledge for the design of a range of therapies to best restore the abundance of IGF within the IUGR fetus to improve perinatal and later outcomes.

出生前发育不良或宫内生长受限（IUGR），如怀孕阶段的体重轻，短或瘦，大大增加了出生前后和婴儿期疾病和死亡的风险。IUGR增加了窒息、血糖控制不良、体温过低、呼吸困难、神经系统问题和免疫功能低下的风险，其中许多问题持续存在。IUGR是产科和生殖医学中最常见的临床问题之一，在澳大利亚非土著社区出生的IUGR婴儿约占6%，在土著社区出生的IUGR婴儿占7%至17%。尽管这些不良后果对个体的健康在整个生命中，我们目前没有任何有效的治疗方法来治疗IUGR。小婴儿大多是出生前氧气和营养供应不足的结果，这是由于母亲获得胎盘将其输送给生长中的胎儿的能力受损，或者由于胎盘本身功能不良。这种宫内营养不良不仅减缓生长，而且损害一系列身体功能的发育，导致IUGR疾病和死亡的风险增加。出生前用于治疗IUGR的疗法需要恢复氧气和营养物质的供应或促进生长和功能发育。我们已经发现，对IUGR胎儿（其具有低水平的IGF-I）给予主要的生长促进激素胰岛素样生长因子-I（IGF-I），可促进其生长。因此，该项目将确定直接给予IUGR胎儿这种激素是否会恢复发育和出生前的生长，改善功能，从而改善出生后的生存和健康。如果成功的话，第一个有效的方法来产前治疗IUGR将被确定，并将提供必要的知识，设计一系列的治疗，以最好地恢复丰富的IGF在IUGR胎儿，以改善围产期和以后的结果。